The KALM-1 randomized double-blind placebo-controlled phase III trial showed that intravenous difelikefalin, a selective κ-opioid receptor agonist, significantly reduces itch intensity in haemodialysis patients with uraemic pruritus. However, 49% of difelikefalin-treated patients showed no improvement. In light of the increasing number of patients with end-stage renal disease, additional treatments are sorely needed.

中文翻译：

---

缓解尿毒症瘙痒症更近一步。

KALM-1随机双盲安慰剂对照的III期临床试验表明，静脉注射地非利法林是一种选择性的κ阿片受体激动剂，可显着降低尿毒症瘙痒的血液透析患者的瘙痒强度。但是，接受双铁利法林治疗的患者中有49％的患者无改善。鉴于终末期肾脏疾病患者的数量不断增加，因此迫切需要其他治疗方法。